chrisvoncsefalvay/vaers-outcomes huggingface dataset:
AFTER RECEIVING THE 2ND DOSE OF PFIZER COVID VACCINE, MY HUSBAND EXPERIENCED A HARD, TENDER/PAINFUL LUMP ON HIS RIGHT SHOULDER, WHICH WE BELIEVED TO BE A SWOLLEN LYMPH NODE BASED ON APPEARANCE AND LOCATION, AND WHICH LASTED APPROXIMATELY 10 DAYS. THE EVENING AFTER RECEIVING THE THIRD/BOOSTER DOSE, HE COMPLAINED OF PAIN IN HIS UPPER BACK/SHOULDER AREA. THAT NIGHT, I NOTICED THAT HE HAD A SLIGHTLY SMALLER BUT SIMILAR-LOOKING HARD LUMP ON HIS SHOULDER. THE NEXT MORNING, HE INITIALLY STATED HE FELT AS IF HE'D "SLEPT WRONG," BECAUSE HIS SHOULDERS/BACK WERE SORE. AS THE DAY PROGRESSED, HE FELT MORE SORENESS MOVING DOWN THE RIGHT SIDE OF HIS BACK, ALONG HIS SPINE. THE NEXT DAY, HE DESCRIBED IT AS FEELING LIKE HE'D "DONE A TON OF SQUATS," BECAUSE HE HAD SORENESS/TENDERNESS ALONG HIS BACK AND INTO HIS RIGHT BUTTOCK. WE CANNOT THINK OF ANY EXPLANATION FOR THESE SYMPTOMS EXCEPT THE VACCINE.
patient after getting the vaccine felt dizzy , stayed with him and the father to make sure he is feeling better , the patient said he  feels much better and the father said that he son looks good , verified with patient said he doesn't  feel dizzy anymore
Rash Papular; vaccination site pain; This spontaneous case was reported by a consumer and describes the occurrence of RASH PAPULAR (Rash Papular) and VACCINATION SITE PAIN (vaccination site pain) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Feb-2021, the patient experienced RASH PAPULAR (Rash Papular) and VACCINATION SITE PAIN (vaccination site pain). At the time of the report, RASH PAPULAR (Rash Papular) and VACCINATION SITE PAIN (vaccination site pain) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information not provided. Concomitant medications were not provided.
Inadvertently given a dose of Infanrix / 46 years old; inadvertently given a dose of Infanrix instead of Boostrix; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 46-year-old female patient who received DTPa (Infanrix) (batch number 7EC55, expiry date 29th April 2023) for prophylaxis.   Co-suspect products included dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 6th August 2021, the patient received Infanrix and Infanrix Pre-Filled Syringe Device. On 6th August 2021, unknown after receiving Infanrix and Infanrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration and wrong vaccine administered. On an unknown date, the outcome of the inappropriate age at vaccine administration and wrong vaccine administered were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not reported but it could be 45 or 46 years. The health care professional reported that, the patient received Infanrix instead of Boostrix, which led to inappropriate age at vaccine administration and wrong vaccine administered. No further details were provided. The reporter consented to follow up via mail. This is one of three cases reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021168391:same reporter US-GLAXOSMITHKLINE-US2021168394:same reporter
fever 100 degrees, lethargy, aches, cold symptoms, tiredness , dizziness Janssen COVID-19 Vaccine EUA
This case was reported by a pharmacist and described the occurrence of erythema of cheek in a 57-year-old female subject who was vaccinated with TWINRIX. On 11 July 2013 at 18:00 the subject received 1st dose of TWINRIX (.5 ml, unknown, left arm) and experienced vaccine under dose. The subject received a 0.5 ml dose instead of the indicated 1 ml dose. On 20 July 2013, 9 days after vaccination with TWINRIX, the subject experienced erythema of cheek, heart sensation in cheek, and itchy cheek. Co-suspect medications included Omeprazole, Ondansetron and Lactulose solution. The subject developed a "reactions on one of her cheeks in the form of redness, a feeling of heat and itchiness". She had "recently" started using Omeprazole, Ondansetron and Lactulose solution and pharmacist was trying rule each of these out as the cause of the events too. At the time of reporting the outcome of the events was unspecified.
Redness, Swelling, Itching at injection site immidiately after injection that lasted 3-4 days. Tongue swelling that started 2 days after vaccine administered and lasted 1-2 days.
Vomiting; Headache; temperature; major fatigue; Chiills; body aches; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non pregnant female patient received second dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration in the right arm on 17Mar2021 at 15.00 (at the age of 48-year-old) as a single dose for COVID-19 immunisation. Medical history included sulfate allergy. Patient was taking concomitant medication however drug was unspecified . The patient previously received first dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration on an unspecified date.  Prior to the vaccination, the patient was not diagnosed with COVID-19.  The patient had been tested for COVID-19 nasal swab test on 22Jan2021 which resulted negative. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Mar2021 at 07:00, the patient experienced vomiting, headache, temperature, body aches, chills and major fatigue. The patient took Tylenol as therapeutic measure for the events. The clinical outcome of vomiting, headache, temperature, body aches, chills and major fatigue were recovering.   Information about batch number cannot be obtained. No further information is expected.
Had headache, some joint pain in knees and hands, extremely tired. Symptoms last for about two days. Injection site was sore so applied ice off and on.
While enroute home on the bus about 2:30 pm  heart rate suddenly became rapid, chest tightened and breathing Became labored ? because of my past sensitivities, I carry Benedryl.  I took one and by the time I arrived at destination symptoms had subsided some ? five hours later chest tightness returned - so kept taking Benedryl at 6 hour intervals until 10 pm March 11 when ease of breathing returned - called doctor morning of March 11 and was told to continue Benedryl until symptoms improved
Fever for three days 100-102. Lethargy and listlessness.  Fussy, laying on floor, wouldn't sleep, 4th day- body rash that started on neck and lower torso then whole body including face and hair.
Patient did not report any symptoms at the moment. Patient was advised to monitor for symptoms and call clinic if needed.
Helicobacter pylori infection; Drug effect decreased; COVID-19; COVID-19; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4356088-00.  A 20-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown), all intramuscular for covid-19 immunisation; adalimumab (HUMIRA), (Batch/Lot number: unknown) at citrate free, subcutaneous for hidradenitis; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), as dose 3 (booster), single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant) all with onset Oct2021, outcome "recovered" and all described as "COVID-19"; HELICOBACTER INFECTION (non-serious), outcome "unknown", described as "Helicobacter pylori infection"; THERAPEUTIC PRODUCT EFFECT DECREASED (non-serious), outcome "unknown", described as "Drug effect decreased". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. The action taken for adalimumab was unknown.  The reporter considered "covid-19", "helicobacter pylori infection" and "drug effect decreased" related to BNT162b2.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the available information, there is a reasonable possibility of a causal relationship between the suspect vaccine BNT162B2 (COMIRNATY) and reported events Drug ineffective and COVID - 19 which cannot be fully assessed/excluded. The case will be reassessed if additional information becomes available.
She missed her 3rd dose of Gardasil; Description: Customer reports she missed her 3rd dose of GARDASIL 9 that was scheduled to be given 03/2020.; No additional AE. No PQC. No additional information provided.; This spontaneous report has been received from a consumer, a female patient of unknown age, who referred about herself. Information about her pertinent medical history, concurrent conditions, concomitant medications and previous drug reactions and allergies was not provided.  On unknown dates, the patient received the first and second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), 1 dosage form (reported also as "1 dose"), for prophylaxis (formulation, strength, frequency, route of administration, anatomical location were not provided; lot number and expiration were unknown by the reporter).  The patient reported that she missed her third dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) that was scheduled to be given on an unknown day in March 2020 (inappropriate schedule of product administration) (circumstance or information capable of leading to medication error).  No additional information was provided (no adverse event).
1. Diarrhea [R19.7] Afebrile, no abdominal rigidity, no melena or hematochezia. Diarrhea has been ongoing for about 1 year and had improved but starting in the past 24 hours has flared. He had negative stool studies in the past with positive FOBT. ? IBS. Discussed supportive care measures. Will order labs as does not look like this has been done in the past as well as repeat fecal occult and COVID 19 test (low suspicion for this but have ordered in order to facilitate f/u as GI symptoms are technically a symptom of COVID), however advised pt to call PCP office tomorrow to arrange follow up to discuss possible repeat stool studies, EGD/colonoscopy, and/or GI referral (depending on lab studies may benefit from imaging as well). Reviewed s/s that warrant urgent re-valuation. Pt verbalizes understanding and is agreeable with plan.  PCP Requests: Calprotectin Fecal by Immunoassay, STOOL, Routine, Order for Future Visit, Start: 12/07/21, ONCE, Diarrhea | Occult blood in stools, 12/07/21 9:00:00 EST, 109941123 Ova and Parasites, STOOL, Routine, Order for Future Visit, Start: 12/07/21, ONCE, Diarrhea, 12/07/21 9:00:00 EST, 109941123 Stool Culture, STOOL, Routine, Order for Future Visit, Start: 12/07/21, ONCE, Diarrhea, 12/07/21 9:00:00 EST, 109941123
pt recv first dose; p/ 7 days exp headache, vomiting, fever spikes; sx resolved w/in 7 days. pt recv second dose; w/in 24 hr exp low grade fever; resolve w/in 48 hr; tx was antibiotic therapy
The pt developed cellulitis at the left upper thigh injection site with 5 1/2" x 3 1/2" red area that warm to the touch. Treated with Keflex
After one month on my second shot vaccine started itching and bumps appearing in arms and back body. After 10-15 mins it will disappear.  This happens 4 to 5 times a day. This causes mentally depressed and discomfort.
administration of improperly stored vaccines; This spontaneous report was received from a medical assistant referring to a 4 years old patient of unknown gender. Information about pertinent medical history, drug reaction/allergy and concomitant medication was not provided.   On 27-AUG-2020, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck)(VARIVAX) (lot # S035125, expiration date 04-NOV-2021; strength, vaccine dosage detail and route of administration were not reported) for prophylaxis (product storage error). Current temperature excursion was 6 Fahrenheit degrees to 14 Fahrenheit degrees (10.56 Fahrenheit degrees) for 50 minutes. Previous temperature excursion was 6 Fahrenheit degrees to 14 Fahrenheit degrees (8.47 Fahrenheit degrees) for 30 minutes. No product quality complaint (PQC) was identified. Data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2009USA000777: US-009507513-2009USA000747: US-009507513-2009USA000676: US-009507513-2009USA000699: US-009507513-2009USA000749:
Initial report was received from a patient on 21 October 2011. A 72-year-old female patient had received a FLUZONE injection in left deltoid, lot number UH476AC on 06 October 2011. On 08 October 2011, the patient developed a scratchy throat, two day later on 10 October 2011; she developed aches, fever, cough, sinus swelling and chills which resolved on 14 October 2011. The course of treatment was not reported. No further information was available at the time of the report. The patient outcome for scratchy throat was reported as not recovered/not resolved. Follow-up information was received from a healthcare professional on 20 January 2012. The patient was not seen in follow-up for the symptoms described and no corrective treatment provided. The patient outcome was reported as recovered/resolved on November 2011. Documents held by sender: none.
Started to develop symptoms of COVID19 around Feb 1st, 2022. At first was a mild cough and minor headache. By the morning of Feb 3rd, I was too sick to work and symptoms included a minor fever, cough, lots of fatigue, and a headache. Treatment was OTC meds, mostly just ibuprofen for the headache and "alka-seltzer cold and flu" for the cough. By Feb 9th I had recovered good bit and started returning to work but was still not back to 100%. By Feb 14th, I was feeling good again but a minor cough persisted for a few more weeks before it stopped.
Morning of 10/26/2021, felt tired and with a headache (like a bad hangover). Rested during the day, plenty of fluids. Morning of 10/27/2021, mostly symptoms were gone. In the afternoon (around 5pm), headache came back. Took Tylenol and went to bed at some point Morning of 10/28/2021, no headache in bed, but about 30 minutes after getting out of bed, despite hydration, headache came back
wasn't feeling well; body aches; arm was sore; slight joint pain; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (wasn't feeling well), PAIN (body aches), PAIN IN EXTREMITY (arm was sore) and ARTHRALGIA (slight joint pain) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     The patient's past medical history included Shaking of hands (right arm and hand shaking,) on 04-Jan-2021.    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Jan-2021, the patient experienced MALAISE (wasn't feeling well), PAIN (body aches), PAIN IN EXTREMITY (arm was sore) and ARTHRALGIA (slight joint pain). At the time of the report, MALAISE (wasn't feeling well), PAIN (body aches), PAIN IN EXTREMITY (arm was sore) and ARTHRALGIA (slight joint pain) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Concomitant medications were not provided Treatment medications were not provided   This case was linked to MOD-2022-438597, MOD-2022-438711 (Patient Link).
COVID-19; fever; tiredness; cough; headache; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19), PYREXIA, FATIGUE, COUGH, and HEADACHE in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041l20a) for COVID-19 vaccination.     NO Medical History Information was reported.     On 24-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Jan-2021, the patient experienced HEADACHE. On 28-Jan-2021, the patient experienced COVID-19 (COVID-19), PYREXIA, FATIGUE, and COUGH. The patient was treated with PARACETAMOL for Adverse event, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) had not resolved and PYREXIA, FATIGUE, COUGH, and HEADACHE outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Jan-2021, SARS-CoV-2 test: (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant Concomitant medications were reported. This case was received via an unknown source (no reference has been entered for a health authority) on 29-Jan-2021 and was forwarded to Moderna on 30-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19), PYREXIA, FATIGUE, COUGH, and HEADACHE in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041l20a) for COVID-19 vaccination.     NO Medical History Information was reported.     On 24-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Jan-2021, the patient experienced HEADACHE. On 28-Jan-2021, the patient experienced COVID-19 (COVID-19), PYREXIA, FATIGUE, and COUGH. The patient was treated with PARACETAMOL for Adverse event, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) had not resolved and PYREXIA, FATIGUE, COUGH, and HEADACHE outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Jan-2021, SARS-CoV-2 test: (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant Concomitant medications were reported.
Patient was sitting down in chair along with his wife and she noticed him pass out for just a few seconds. His wife called for the nurse practitioner in the office closest to their chairs.  The patient was cool and clammy, pale in color. The nurse checked his vital signs, applied a cool compress to the back of his neck, and fanned him with cool air. After a few minutes the patient's skin color returned to normal, his temperature improved and he was back to himself. He was advised to sit for an additional 30 minutes since the event so that the nurse and pharmacist could monitor him.
When received the injection at 1:45 pm on a Friday, was extremely painful, subsided a little bit for a couple hours then around 4:30pm arm was so sore could not lift to side at all, and to lift forward had to use other arm for support. At 9 pm that night developed bad headache, body aches, joint pain, nausea, with chills and sweats throughout the night, these symptoms continued all the next day and on through Saturday evening, and around 4 am Sunday morning symptoms started subsiding and was able to sleep from around 4 am to 9 am Sunday and when awakened at that time, symptoms had notably subsided and by mid-day Sunday felt pretty good and could resume normal activities, with exception of very sore muscle at injection site. Pain in the muscle at injection site (left upper arm) resolved completely by 6th/7th day.
Neuropathy; Sweating; barely can walk; Fogginess in her mind; sleep problems; canceled appointment for second shot even though her HCP advised her to get it; Chilis; This spontaneous case was reported by a consumer and describes the occurrence of NEUROPATHY PERIPHERAL (Neuropathy) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015m20a) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced NEUROPATHY PERIPHERAL (Neuropathy) (seriousness criterion medically significant), HYPERHIDROSIS (Sweating), GAIT DISTURBANCE (barely can walk), FEELING ABNORMAL (Fogginess in her mind), SLEEP DISORDER (sleep problems), INTENTIONAL PRODUCT USE ISSUE (canceled appointment for second shot even though her HCP advised her to get it) and CHILLS (Chilis). At the time of the report, NEUROPATHY PERIPHERAL (Neuropathy), HYPERHIDROSIS (Sweating), GAIT DISTURBANCE (barely can walk), FEELING ABNORMAL (Fogginess in her mind) and CHILLS (Chilis) had not resolved, SLEEP DISORDER (sleep problems) was resolving and INTENTIONAL PRODUCT USE ISSUE (canceled appointment for second shot even though her HCP advised her to get it) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was withdrawn on an unknown date.       No relevant concomitant medications were provided. No treatment information was provided. This case of a 75-year-old female patient who canceled appointment for second (Intentional deviation from dosage regimen) due to events experienced following the first dose of mRNA-1273.  The event of Intentional deviation from dosage regimen is assessed as not applicable. Based on temporality and excluding other etiologies, the causal relationship between the other events and the product use cannot be excluded. Chills is consistent with the product known safety profile.   This case was linked (E2B Linked Report).; Sender's Comments: This case of a 75-year-old female patient who canceled appointment for second (Intentional deviation from dosage regimen) due to events experienced following the first dose of mRNA-1273.  The event of Intentional deviation from dosage regimen is assessed as not applicable. Based on temporality and excluding other etiologies, the causal relationship between the other events and the product use cannot be excluded. Chills is consistent with the product known safety profile.
I had post nasal drip, my nose was runnier and a cough; no more that I have right now. I had a COVID-19 test and that's how I found out I had it, otherwise I wouldn't have known. I took PAXLOVID.
Overnight after receiving covid-19 updated Moderna vaccine, on left arm, had swelling and redness on the upper arm.
Muscle weakness in legs and arms , numbness in fingers and both hands unable to  write . Unable to walk without assistance .  No change in symtoms